Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $167.23M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.04M
Average 1.37M
Returns on capital
Eledon Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-56.3%
avg -217.2%
ROIC
-55.1%
avg -71.6%
ROA
-27.0%
avg -71.9%
Analysis
ROA is currently the strongest return metric at -27.0% versus its period average of -71.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David-Alexandre C. Gros | Chief Executive Officer & Non Independent Director | USD 984.41K | 54 | 168.66K | 0.28% |
Steven N. Perrin | President, Chief Scientific Officer & Non Independent Director | USD 792.16K | 60 | — | — |
Paul Sean Little | Chief Financial Officer | USD 717.38K | 61 | 75.00K | 0.13% |
Bryan E. Smith | General Counsel, Corporate Secretary & Chief Compliance Officer | USD 377.14K | 46 | 64.50K | 0.11% |
David Hovland | Chief Regulatory Officer | — | — | — | — |
Sepideh Habibi | VP and Head of Safety & Pharmacovigilance | — | — | — | — |
John Herberger | Vice President of Technical Operations | — | — | — | — |
Marina Escudero | Vice President & Head of Clinical Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 31, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Eledon Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ELDN's management, answered from reported figures.
Who manages ELDN?
Eledon Pharmaceuticals, Inc. (ELDN) lists 8 active executives. The top listed executive is David Hovland, Chief Regulatory Officer.
Are ELDN insiders buying or selling?
Recent insider activity shows net buying of $69.66M.
Continue the stock analysis
Jump to another research area for this company.